Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus

Endocrine Journal

Volumn 58, Issue 10, 2011, Pages 869-877

  Nagai, Etsuko ^a   Katsuno, Tomoyuki ^a   Miyagawa, Jun ichiro ^a   Konishi, Kosuke ^a   Miuchi, Masayuki ^a   Ochi, Fumihiro ^a   Kusunoki, Yoshiki ^a   Tokuda, Masaru ^a   Murai, Kazuki ^a   Hamaguchi, Tomoya ^a   Namba, Mitsuyoshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Alphaglucosidase inhibitor; Glucagon; Glucagon like peptide 1 (GLP 1); Glucose dependent insulinotropic peptide (GIP)

Indexed keywords

1,5 ANHYDROSORBITOL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIGLITOL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HORMONE RESPONSE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MALE; TREATMENT OUTCOME; URINARY EXCRETION;

1-DEOXYNOJIRIMYCIN; ADULT; AGED; ALPHA-GLUCOSIDASES; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; MALE; MIDDLE AGED; SERUM ALBUMIN; WEIGHT LOSS; YOUNG ADULT;

EID: 80055082813     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K11E-129     Document Type: Article

References (22)

1. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986.
2. The Diabetes Control and Complications Trial Research Group (1995) Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75: 894-903.
3. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group (1999) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22: 99-111.
4. Leahy JL, Cefalu WT (2002) Insulin Therapy. New York: University of Vermont College of Medicine Burlington, Vermont Marcel Dekker: 87-112.
5. Katsuno T, Hamaguchi T, Nagai E, et al (2008) Efficacy of Insulin Glargine on Basal Insulin Supplementation in Japanese Type 1 Diabetes Patients Treated with Basalbolus Injection Therapy. J Japan Diab Soc 51: 983-990. (In Japanese)
6. Ahr HJ, Boberg M, Brendel E, et al (1997) Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 47: 734-745.
7. Nemoto M, Tajima N, Kawamori R (2011) Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled doubleblind comparative study. Acta Diabetol 48: 15-20.
8. Seino Y, Nanjo K, Tajima N, et al (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 53: 450-467. (In Japanese)
9. Dimitriadis G, Hatziagellaki E, Alexopoulos E, et al (1991) Effect of alpha-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus. Diabetes Care 14(5): 393-398.
10. Hillman RJ, Scott M, Gray RS (1989) Effect of alphaglucosidase inhibition on glucose profiles in insulin dependent diabetes. Diabetes Res. 10(2): 81-84.
11. Dimitriadis G, Hatziagelaki E, Ladas S, et al (1988) Effects of prolonged administration of two new alphaglucosidase inhibitors on blood glucose control, insulin requirements and breath hydrogen excretion in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest. 18(1): 33-38.
12. Kubo K, Watada H, Kawamori R (2010) Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients. J Diabetes Invest 1: 60-65.
13. Arakawa M, Ebato C, Mita T, et al. (2008) Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 57: 1299-1306.
14. Aoki K, Masuda K, Miyazaki T, et al (2010) Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 57: 667-672.
15. Lee A, Patrick P, Wishart J, et al (2002) The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4: 329-335.
16. Narita T, Katsuura Y, Sato T, et al (2009) Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 26: 187-188.
17. Hare KJ, Knop FK, Asmar M, et al (2009) Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 94: 4679-4687.
18. Degn KB, Brock B, Juhl CB, et al (2004) Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53: 2397-2403.
19. Dunning BE, Foley JE, Ahren B (2005) Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48: 1700-1713.
20. Vilsboll T, Krarup T, Madsbad S, et al (2003) Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114: 115-121.
21. Kloppel G., Lohr M, Habich K, et al (1985) Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 4: 110-125.
22. Yamada Y, Miyawaki K, Tsukiyama K, et al (2010) Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 55: s86-s91.